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Abstract
Background Zidovudine (ZDV) has been associated with
risk of haematological toxicity. Safety data from clinical
trials is generally limited to 48 weeks. We assessed the
short- and mid-term toxicity of ZDV/lamivudine (3TC)
fixed-dose combination scored tablets in HIV-infected
children followed in the European Pregnancy and
Paediatric HIV Cohort Collaboration (EPPICC) network.
Methods Fourteen cohorts provided data on patients
<18 years of age taking ZDV/3TC scored tablets be-
tween 2008 and 2012. Rates of Division of AIDS
(DAIDS) grade ≥3 laboratory adverse events (AEs) for
hepatobiliary and haematological disorders were estimat-
ed by duration on drug (<12, 12–24, >24 months).
Clinical adverse events and reasons for tablet discontin-
uation were described.
Results Of 541 patients on ZDV/3TC, 388 (72%) had weight
and dose data available, of whom 350 (90%) weighed ≥14 kg
and were eligible for tablet use; 161 (41%) were aged
<10 years on an approved dose, 189 (49%) aged ≥10 years
on an approved dose, and 30 (8%) were on an unapproved
dose. Median age at ZDV/3TC start was 10 years, and 79%
had taken ART previously (60% had prior exposure to ZDV/
3TC). Overall rates of grade ≥3 AEs for absolute neutrophil
counts, bilirubin, haemoglobin, platelet counts, white blood
cell counts (WBC), alanine aminotransferase (ALT) and
aspartate aminotransferase (AST) were ≤2/100 person years
(PY) for patients taking approved doses. Two hundred thirty-
three (43%) patients were not on ZDV/3TC tablets at most
recent follow-up; a small number (17 (7%)) discontinued due
to AEs (17 (7%)), and the most common reason for discon-
tinuation was treatment simplification (73 (31%)).
Conclusions Scored ZDV/3TC tablets, both approved
and taken off-label, appear to be well tolerated with
few side effects. Few patients discontinued treatment
due to toxicity. As ZDV/3TC tablets are taken with
other antiretrovirals, it is difficult to infer association
between toxicities and specific agents, highlighting the
importance of widening long-term pharmacovigilance to
a broader spectrum of drug combinations.
Keywords Pharmacovigilance . Children . Antiretroviral
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Introduction
Zidovudine (ZDV)/lamivudine (3TC) is a first-line NRTI
backbone for paediatric HIV infection. A fixed-dose
combination of 300 mg ZDV with 150 mg 3TC
(Combivir®) was initially approved in Europe in 1998.
Subsequently, a scored tablet formulation of ZDV/3TC
was approved in 2008 for paediatric HIV treatment for
those weighing ≥14 kg or requiring dose adjustment, or
patients experiencing dose-limiting adverse reactions.
Dosing of ZDV/3TC is by weight bands [1].
ZDV has been associated with the risk of haemato-
logical toxicity [2], and WHO guidelines recommend
avoiding ZDV for first-line treatment for patients with
severe anaemia [1]. However, the ARROW and
CHAPAS-3 trial data [3, 4] indicated no increased anae-
mia risk among children on ZDV, suggesting this may
The original publication of the paper contains a mistake. There should be
no author name present in the article.
* The European Pregnancy and Paediatric HIV Cohort Collaboration
(EPPICC) study group in EuroCoord
a.judd@ucl.ac.uk;
1 MRC Clinical Trials Unit at UCL, Institute of Clinical Trials and
Methodology, Ali Judd, University College London, Aviation House,
125 Kingsway, London WC2B 6NH, UK
Eur J Clin Pharmacol (2017) 73:463–468
DOI 10.1007/s00228-016-2182-2
be caused predominantly by chronic HIV or other infec-
tions rather than ART. The CNAA3006 study provided
safety data on the use of ZDV/3TC in patients aged
6 months to 13 years; however, this study did not eval-
uate the scored tablet formulation [5]. They found that
ZDV/3TC was well tolerated with <10% of participants
experiencing a treatment-limiting adverse event (AE)
and only 3% of patients experiencing a grade 3/4 anae-
mia abnormality.
Longer-term follow-up is essential to understand the
safety of antiretroviral drugs beyond the 48 weeks of
licencing trials. We investigated the short- and mid-
term toxicity among children receiving ZDV/3TC scored
tablets as part of routine care. Patients were followed in
observational cohorts participating in the European
Pregnancy and Paediatric HIV Cohort Collaboration
(EPPICC), within which a pharmacovigilance pro-
gramme has been running since 2009 [6, 7].
Methods
HIV-infected paediatric patients, aged <18 years from
14 cohorts participating in EPPICC’s pharmacovigilance
programme (part of the EuroCoord network) who ever
received ZDV/3TC scored tablets between 2008 and
2012, were included. Individual participating cohorts
were responsible for gaining their own ethics approval.
Data collected included demographics, deaths, losses to
follow-up and follow-up data (both pre- and post-ZDV/
3TC scored tablets) for patient weight, ART, Centres for
Disease Control and Prevention (CDC) category C
(AIDS) events, CD4 and HIV-1 RNA, key haematology
and biochemistry results and serious adverse events
(SAEs). Data up to February 2014 were merged, using
the HIV Cohorts Data Exchange Protocol specification
(www.hicdep.org).
Patients were considered to be on an approved dose
if taking ZDV/3TC scored tablets as licenced, i.e. ≥14–
< 20 kg, half a tablet (75/150 mg) b.i.d; ≥20–< 30 kg,
half a tablet (75/150 mg) in morning, whole tablet (150/
300 mg) in evening; and ≥30 kg, whole tablet (150/
300 mg) b.i.d. Patients on other doses within these
weight bands or weighing <14 kg were considered to
be on an unapproved dose.
Biochemical results were graded using the Division
of AIDS (DAIDS) categorisation for paediatric AEs
(Appendix Table 2) [8]. Rates of grade ≥3 AEs were
calculated within four distinct time periods on scored
tablet (<12, 12–24 and >24 months) and age starting
scored tablet (<10 and ≥10 years) where there were
n ≥ 30 patients in each group in follow-up for approved
doses. Laboratory analyses were restricted to patients
with ≥3-month follow-up after start of the tablets and
were censored at 30 days after tablet discontinuation.
Patients were censored at their first grade ≥3 event
within each time period. Clinical SAEs and reasons for
tablet discontinuation were also described. Analyses
Table 1 Characteristics of patients taking ZDV/3TC scored tablets
(n = 541)
N (%) / median [IQR]
Country
UK/Ireland 96 (18)
Other European countriesa 152 (28)
Russia 90 (17)
Thailand 203 (38)
Male gender 250 (46)
Ethnic group
White 151 (28)
Black African 104 (19)
Asian and other 236 (44)
Unknown 50 (9)
Mode of HIV infection
MTCT 450 (83)
Other 13 (2)
Unknown 78 (14)
Ever AIDS event 145 (27)
Median age at ART start (years) 6 [2, 9]
Median age at ZDV/3TC scored
tablet start (years)
10 [7, 13]
ART experienced (≥1 ART drug)
before ZDV/3TC scored tablets
429 (79)
Median duration on ART before
ZDV/3TC scored tablet start (years)
4 [1, 6]
Exposure to ZDVand 3TC before
starting ZDV/3TC scored tablets
327 (60)
Median VL at ZDV/3TC start (log10c/mL) 1.7 [1.6, 3.3]
Median CD4 cell count ZDV/3TC
start (cells/mm3)
660 [416, 972]
Median CD4% at ZDV/3TC start 28 [19, 34]
Median time on ZDV/3TC scored
tablets (months)b
30 [17, 56]
Time to discontinuation of ZDV/3TC
(n = 233)
<1 month 11 (5)
1–<6 months 29 (12)
6–<12 months 32 (14)
≥12 months 161 (69)
Reasons for stopping tablets (n = 233)
Treatment failure (immunological/
virological)
42 (18)
Toxicity/side effects 17 (7)
Death 7 (3)
Non-compliance 9 (4)
Patient’s wish/decision 7 (3)
Co-morbidity 1 (0)
Physician’s decision 3 (1)
Simplified treatment available 73 (31)
Better safety profile 1 (0)
Unknown 73 (31)
a Other European countries are Belgium, Greece, Italy, Poland, Portugal,
Romania, Spain and Sweden
b For those still on ZDV/3TC at the last follow-up
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were undertaken using Stata version 14.0 (Stat Corp,
College Station, TX, USA).
Results
Overall, 541/3139 (17%) patients <18 years on ART in
14 cohorts ever took ZDV/3TC scored tablets between
2008 and 2012. The majority were from the Thai
(38%), UK/Ireland (18%) and Russian (17%) cohorts,
and among those with known mode of HIV acquisition,
almost all were perinatally HIV-infected (Table 1).
Twenty-five (5%) patients were co-infected with
hepatitis-C virus and 23 (4%) with hepatitis-B virus.
Of the 145 (27%) patients ever diagnosed with AIDS,
22 (15%) were after tablet start. At the start of ZDV/
3TC scored tablets, 190 (35%) had previously received
1–3, 215 (40%) 4–7, and 24 (4%) ≥8 ART drugs; 327
(60%) ZDV and 3TC.
Overall, 388 (72%) had weight and dose data avail-
able at start of ZDV/3TC tablets, of whom 350 (90%)
weighed ≥14 kg and were taking an approved dose for
weight (161 (46%) aged <10 years and 189 (54%)
≥10 years); 30 (8%) weighed ≥14 kg and were taking
an unapproved dose for weight (26 patients were under-
dosed and 4 were over-dosed), and 8 (2%) had weight
<14 kg on any dose. Thirty-two percent of patients
<18 years on ART were taking an NNRTI and 60% a
boosted PI.
The incidence rates of DAIDS grade ≥3 events were
generally low (Fig. 1). Five (4%) patients aged
<10 years and 6 (4%) ≥10 years at start of ZDV/3TC
tablets had grade ≥3 neutropenia. Two (1%) patients
aged <10 years had a grade ≥3 alanine aminotransferase
(ALT) event (one <12 and one 12–24 months after
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Fig. 1 Incidence of grade ≥3 adverse events by duration of ZDV/3TC scored tablets (n = 145 < 10 years with weight ≥14 kg, n = 166 ≥ 10 years with
weight ≥14 kg)
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starting ZDV/3TC) and two (1%) ≥10 years. One pa-
tient aged <10 years (<1%) had a grade ≥3 aspartate
aminotransferase (AST) event 12–24 months after
starting ZDV/3TC. Five (4%) patients aged <10 years
had grade ≥3 hyperbilirubinemia and five patients (4%)
≥10 years (four within 12 months of starting ZDV/
3TC). Five (4%) patients aged <10 years had grade ≥3
anaemia (four within 12 months of starting ZDV/3TC)
and 4 (2%) ≥10 years. Two (2%) patients aged
<10 years had grade ≥3 platelet results (both <12 months
after starting ZDV/3TC) and 2 (1%) ≥10 years (1 within
12 months, and 1 after 24 months). There was only 1
grade ≥3 WBC event among patients aged ≥10 years.
Among 22 patients taking unapproved doses of ZDV/3TC
with ≥1 laboratory test, 4/15 (20%) had grade ≥3 neutropenia,
of which two subsequently resolved; all the four were aged
≥10 years at the time of the grade ≥3 result. One (5%) had
grade ≥3 hyperbilirubinemia reported <12 months after
starting ZDV/3TC and again at 12–24 months. Of the eight
pa t ien ts wi th weight <14 kg one had grade ≥3
hyperbilirubinemia.
Among 159 patients on approved dose with clinical data,
there were five SAEs causally related to ZDV/3TC, all aged
<10 years at start of ZDV/3TC; anaemia (n = 4) and neutro-
penia (n = 1). There were no clinical SAEs considered caus-
ally related to the tablets for patients aged ≥10 years at start of
ZDV/3TC on an approved or unapproved dose.
During follow-up, 12 (2%) patients died, of whom seven
were taking ZDV/3TC at death. Nine deaths were patients
aged ≥10 years at start of ZDV/3TC and on an approved dose,
and the deaths were reported as HIV-related (n = 5) or AIDS-
defining (n = 1) events, suicide (n = 1) or unknown causes
(n = 2; 21 and 22 months after starting ZDV/3TC scored
tablets). In the unapproved dose group, two deaths were re-
ported during follow-up, one fromHIV-related causes and one
an AIDS-defining event. One death occurred in the <14-kg
weight category and one in a patient with missing dose; one
was taking ZDV/3TC at time of death.
Overall, 233 (43%) patients were not on ZDV/3TC tablets at
the last follow-up, and the main reasons for discontinuations
were treatment simplification (31%) and treatment failure
(18%) (Table 1). Most patients discontinued ≥12 months after
starting ZDV/3TC. Seventeen patients discontinued due to tox-
icity, including abnormal fat redistribution (n = 3), dyslipidaemia
(n = 2) haematological (n = 4), liver (n = 2), nervous system
(n = 2), hypersensitivity reaction (n = 2) and unspecified (n = 2).
Discussion
The findings from this study suggest that ZDV/3TC scored
tablets were received by nearly one in five children cur-
rently on ART in cohorts in Europe and Thailand. In
patients taking the approved doses, rates of grade ≥3 AEs
were generally low and were comparable across children
aged <10 and ≥10 years at the start of ZDV/3TC tablets.
These results are comparable to those of the CNAA3006
study that showed grade ≥3 AEs occurred in ≤30% of par-
ticipants and were mild/moderate in intensity; <10% of the
participants experienced a treatment-limiting AE. Rates of
grade ≥3 AEs were also similarly low to those in children
in our collaboration taking fosamprenavir-, darunavir- and
atazanavir-containing regimens [6, 7]. Discontinuations in
this study, most of which occurred at least 12 months after
starting treatment, were mainly due to treatment simplifi-
cation. A small number of children died, for whom the
most common causes were HIV- or AIDS-related. This is
comparable with CNAA3006 where there was only 1 death
in 103 participants in the ZDV/3TC group, considered un-
related to the study drug.
A limitation of this analysis is that EPPICC cohorts
do not routinely capture mild AEs such as diarrhoea,
vomiting, nausea and choking; thus, it was not possible
to estimate their frequency in this report. Also due to
the small number of grade ≥3 lab events, it was not
possible to stratify rates by country, or to present rates
for those taking unapproved doses. We were also unable
to compare characteristics of patients with and without
SAEs due to the small numbers. As 60% of patients
were exposed to ZDV and 3TC prior to starting ZDV/
3TC scored tablets, the incidence of AEs in this popu-
lation may not be generalizable to children newly ex-
posed to ZDV/3TC. Similarly, since ZDV/3TC is rou-
tinely taken with other antiretroviral drugs, it is difficult
to attribute causality for these occurrences to any one
specific agent, highlighting the importance of widening
long-term pharmacovigilance studies to a broader spec-
trum of drug combinations.
In summary, ZDV/3TC-containing regimens, both ap-
proved and unapproved, appear to be well tolerated in the
paediatric population in Europe and Thailand. No major
post-licencing short- to medium-term safety concerns were
identified in our study.
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